Summary
As the president of Genomic, a corporation specializing in the development of micro-machines, Serano played a pivotal role in pioneering the Micromachine industry. His company was the first to file a patent for a Micromachine treatment targeting Cyberbrain Sclerosis. Following financial losses from the Laughing Man incident, Genomic received government funding to offset the drop in stock value. However, Serano later confessed that the treatment patent was filed prematurely and that the Micromachines produced were ineffective against the disease. Before he could testify to these admissions, Serano was assassinated. The corporate headquarters of Genomic are situated in Holland.
